Chengdu New Radiomedicine
China - ChengduPharmaceutical
Focus: Chengdu New Radiomedicine is a specialized radiopharmaceutical company founded in 2016, focused on oncology and neurology therapeutics. With 51-200 employees, it operates as a mid-cap biotech with a niche portfolio in radiopharmaceuticals and generic medications.
Profile data last refreshed 22h ago · AI intelligence enriched 3w ago
Employees
51-200
Open Jobs
0
About Chengdu New Radiomedicine
AI assessmentNot HiringNo open roles listed right now. Follow Chengdu New Radiomedicine to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Chengdu New Radiomedicine's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
3/9 — Basic
Company HealthSolid
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
1 imminent
PROVAYBLUE
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
Post-LOE
Mature generic IV injection with well-characterized pharmacokinetics; multiple ANDA approvals indicate market saturation and commodity pricing.
Help build intelligence for Chengdu New Radiomedicine
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.